BiPar Sciences, a Brisbane, CA-based developer of cancer drugs, said today it agreed to be acquired by Paris-based Sanofi-Aventis in a deal that could be worth as much as $500 million if the company’s lead drug candidate reaches certain milestones in development. Paul Allen’s Vulcan Capital led a $13 million Series A round in BiPar in 2004. The company is developing PARP inhibitors, which are thought to interrupt signals that allow cancer cells to rapidly proliferate.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
